Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Hum Nutr Diet ; 36(4): 1242-1252, 2023 08.
Article in English | MEDLINE | ID: mdl-36866647

ABSTRACT

BACKGROUND: The long-term effects on people who have had COVID-19 affect nutrition and can be influenced by diet conversely. Specific nutritional guidelines, however, were scarce at the beginning of 2020, and empirical literature was also lacking. Conventional research methodologies needed to be adapted to review the available literature that could be relevant to the United Kingdom and policy documents as well as collect the views of health and care staff. The aim of this paper is to describe the method to develop consensus statements from experts to address the necessary nutritional support and what emerged from this. METHODS: A nominal group technique (NGT) was adapted to the virtual world; we purposefully selected a range of professionals (dietitians, nurses, occupational therapists, etc.) and patients with long-term effects of COVID to present them with the most updated evidence and aim to reach key guidelines to address COVID-19 recovery. RESULTS: We were able to reach consensus statements that were developed and reviewed by relevant healthcare staff at the front line to address the nutritional needs of patients recovering from COVID-19 and those suffering from its long-term effects. This adapted NGT process led us to understand that a virtual repository of concise guidelines and recommendations was needed. This was developed to be freely accessed by both patients recovering from COVID-19 and health professionals who manage them. CONCLUSIONS: We successfully obtained key consensus statements from the adapted NGT, which showed the need for the nutrition and COVID-19 knowledge hub. This hub has been developed, updated, reviewed, endorsed and improved across the subsequent 2 years.


Subject(s)
COVID-19 , Humans , Health Personnel , Social Support , Delivery of Health Care , Nutritional Status
2.
Proc Nutr Soc ; 72(2): 251-60, 2013 May.
Article in English | MEDLINE | ID: mdl-23480778

ABSTRACT

The aim of this review paper is to consider how the principles of clinical audit could be applied to the development of an audit of nutritional care in hospitals and care homes, based on criteria derived from the Essence of Care: Food and Drink. A literature review identified fifteen key papers that included guidance or standards for nutritional care in hospitals or care homes. These were used to supplement the ten factors suggested by the Essence of Care to develop a set of potential audit criteria covering all aspects of the nutritional care pathway including the identification of risk of malnutrition, implementation of nutritional care plans, referral to healthcare professionals for further nutritional assessment and nutritional support strategies. A series of audit tools have been developed, including an organisational level audit tool, a staff questionnaire, a patients' and residents' records audit tool and a patients' and residents' experiences questionnaire. Further issues to consider in designing a national nutritional audit include the potential role of direct observation of care, the use of trained auditors and the scope for including the results of pre-existing local audits. In conclusion, a national audit would need to encompass a very large number of health and care organisations of widely varying sizes and types and a diverse range of people.


Subject(s)
Homes for the Aged/standards , Hospitals/standards , Nutrition Assessment , Aged , Humans , Surveys and Questionnaires , United Kingdom
3.
Infect Control Hosp Epidemiol ; 33(4): 338-45, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22418628

ABSTRACT

BACKGROUND: An antimicrobial stewardship program was fully implemented at the University of Maryland Medical Center in July 2001 (beginning of fiscal year [FY] 2002). Essential to the program was an antimicrobial monitoring team (AMT) consisting of an infectious diseases-trained clinical pharmacist and a part-time infectious diseases physician that provided real-time monitoring of antimicrobial orders and active intervention and education when necessary. The program continued for 7 years and was terminated in order to use the resources to increase infectious diseases consults throughout the medical center as an alternative mode of stewardship. DESIGN: A descriptive cost analysis before, during, and after the program. PATIENTS/SETTING: A large tertiary care teaching medical center. METHODS: Monitoring the utilization (dispensing) costs of the antimicrobial agents quarterly for each FY. RESULTS: The utilization costs decreased from $44,181 per 1,000 patient-days at baseline prior to the full implementation of the program (FY 2001) to $23,933 (a 45.8% decrease) by the end of the program (FY 2008). There was a reduction of approximately $3 million within the first 3 years, much of which was the result of a decrease in the use of antifungal agents in the cancer center. After the program was discontinued at the end of FY 2008, antimicrobial costs increased from $23,933 to $31,653 per 1,000 patient-days, a 32.3% increase within 2 years that is equivalent to a $2 million increase for the medical center, mostly in the antibacterial category. CONCLUSIONS: The antimicrobial stewardship program, using an antimicrobial monitoring team, was extremely cost effective over this 7-year period.


Subject(s)
Academic Medical Centers/economics , Anti-Infective Agents/economics , Drug Costs , Drug Utilization Review , Academic Medical Centers/organization & administration , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Costs and Cost Analysis , Humans , Maryland , Practice Guidelines as Topic , Quality Indicators, Health Care
4.
Antimicrob Agents Chemother ; 52(10): 3558-63, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18663022

ABSTRACT

Hospital-acquired vancomycin-resistant enterococcal bacteremia has been associated with increased hospital costs, length of stay, and mortality. The peptide nucleic acid fluorescent in situ hybridization (PNA FISH) test for Enterococcus faecalis and other enterococci (EFOE) is a multicolor probe that differentiates E. faecalis from other enterococcal species within 3 h directly from blood cultures demonstrating gram-positive cocci in pairs and chains (GPCPC). A quasiexperimental study was performed over two consecutive years beginning in 2005 that identified GPCPC by conventional microbiological methods, and in 2006 PNA FISH was added with a treatment algorithm developed by the antimicrobial team (AMT). The primary outcome assessed was the time from blood culture draw to the implementation of effective antimicrobial therapy before and after PNA FISH. The severity of illness, patient location, and empirical antimicrobial therapy were measured. A total of 224 patients with hospital-acquired enterococcal bacteremia were evaluated, with 129 in the preintervention period and 95 in the PNA FISH period. PNA FISH identified E. faecalis 3 days earlier than conventional cultures (1.1 versus 4.1 days; P < 0.001). PNA FISH identified Enterococcus faecium a median 2.3 days earlier (1.1 versus 3.4 days; P < 0.001) and was associated with statistically significant reductions in the time to initiating effective therapy (1.3 versus 3.1 days; P < 0.001) and decreased 30-day mortality (26% versus 45%; P = 0.04). The EFOE PNA FISH test in conjunction with an AMT treatment algorithm resulted in earlier initiation of appropriate empirical antimicrobial therapy for patients with hospital-acquired E. faecium bacteremia.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteremia/drug therapy , Bacteremia/microbiology , Cross Infection/drug therapy , Cross Infection/microbiology , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , In Situ Hybridization, Fluorescence/methods , Peptide Nucleic Acids/genetics , Adult , Aged , Aged, 80 and over , Algorithms , Enterococcus faecalis/drug effects , Enterococcus faecalis/genetics , Enterococcus faecalis/isolation & purification , Enterococcus faecium/drug effects , Enterococcus faecium/genetics , Enterococcus faecium/isolation & purification , Female , Humans , Male , Middle Aged , Molecular Probes/genetics , Time Factors , Vancomycin Resistance/genetics
5.
Antimicrob Agents Chemother ; 52(7): 2463-7, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18474578

ABSTRACT

Staphylococcus aureus is a common cause of native valve infective endocarditis (IE). Rifampin is often added to traditional therapy for the management of serious S. aureus infections. There are no large, prospective studies documenting the safety and efficacy of adjunctive therapy with rifampin for treatment of native valve S. aureus IE. We reviewed all cases of definite native valve S. aureus IE confirmed by modified Duke criteria in a large urban hospital between 1 January 2004 and 31 December 2005. A retrospective cohort analysis was used to assess the impact of the addition of rifampin to standard therapy. There were 42 cases of S. aureus IE treated with the addition of rifampin and 42 controls. Cases received a median of 20 days of rifampin (range, 14 to 48 days). Rifampin-resistant S. aureus isolates developed in nine cases who received rifampin before clearance of bacteremia (56%), while significant hepatic transaminase elevations also occurred in nine cases, all of whom had hepatitis C infection. Unrecognized significant drug-drug interactions with rifampin occurred frequently (52%). Cases were more likely to have a longer duration of bacteremia (5.2 versus 2.1 days; P < 0.001) and were less likely to survive (79% versus 95%; P = 0.048) than controls. Our results suggest that the potential for hepatotoxicity, drug-drug interactions, and the emergence of resistant S. aureus isolates warrants a careful risk-benefit assessment before adding rifampin to standard antibiotic treatment of native valve S. aureus IE until further clinical studies are performed.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Endocarditis, Bacterial/drug therapy , Heart Valve Diseases/drug therapy , Rifampin/administration & dosage , Staphylococcal Infections/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Bacteremia/drug therapy , Bacteremia/microbiology , Cohort Studies , Drug Interactions , Drug Resistance, Bacterial , Endocarditis, Bacterial/microbiology , Female , Heart Valve Diseases/microbiology , Humans , Liver/drug effects , Male , Middle Aged , Retrospective Studies , Rifampin/adverse effects , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects
6.
J Infect ; 56(2): 126-9, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18082269

ABSTRACT

OBJECTIVES: To determine the impact on the change in epidemiology of Candida species at our institution since the introduction of caspofungin. METHODS: A 5-year retrospective review of all candidemia at a major tertiary care center. Only one episode of candidemia per patient per admission was counted. All antifungal defined daily doses were also collected in this same time period. Regression analysis was performed on the data and correlation statistics among antifungal use and Candida species were assessed using a Pearson correlation analysis. RESULTS: There were 469 individual episodes of candidemia between fiscal year 2002 and 2006 with the rate increasing every year. On regression analysis there was a significant increase in Candida parapsilosis candidemia (R(2)=0.90, p=0.02) and significant increase in caspofungin usage (R(2)=0.80, p<0.01), with a correspondingly significant decline in conventional (R(2)=-0.77, p<0.01) and lipid amphotericin B (R(2)=-0.95, p<0.05) usage. We found correlations between increased caspofungin usage (R(2)=0.94, p=0.017) and increased C. parapsilosis candidemia and decreased Candida tropicalis candidemia (R(2)=0.92, p<0.05) and a trend towards decreased Candida glabrata (R(2)=0.64, p=0.1). CONCLUSIONS: We showed significant correlations between increased caspofungin usage and an increased incidence of C. parapsilosis candidemia and reduction in C. tropicalis candidemia, with a trend towards less C. glabrata candidemia.


Subject(s)
Antifungal Agents/therapeutic use , Candida/classification , Candida/isolation & purification , Echinocandins/therapeutic use , Fungemia , Academic Medical Centers , Antifungal Agents/pharmacology , Candida/drug effects , Candidiasis/drug therapy , Candidiasis/epidemiology , Candidiasis/microbiology , Caspofungin , Drug Resistance, Fungal , Echinocandins/pharmacology , Fluconazole/pharmacology , Fluconazole/therapeutic use , Fungemia/drug therapy , Fungemia/epidemiology , Fungemia/microbiology , Humans , Incidence , Lipopeptides , Maryland , Microbial Sensitivity Tests , Regression Analysis
7.
J Am Med Inform Assoc ; 13(4): 378-84, 2006.
Article in English | MEDLINE | ID: mdl-16622162

ABSTRACT

OBJECTIVE: Many hospitals utilize antimicrobial management teams (AMTs) to improve patient care. However, most function with minimal computer support. We evaluated the effectiveness and cost-effectiveness of a computerized clinical decision support system for the management of antimicrobial utilization. DESIGN: A randomized controlled trial in adult inpatients between May 10 and August 3, 2004. Antimicrobial utilization was managed by an existing AMT using the system in the intervention arm and without the system in the control arm. The system was developed to alert the AMT of potentially inadequate antimicrobial therapy. MEASUREMENTS: Outcomes assessed were hospital antimicrobial expenditures, mortality, length of hospitalization, and time spent managing antimicrobial utilization. RESULTS: The AMT intervened on 359 (16%) of 2,237 patients in the intervention arm and 180 (8%) of 2,270 in the control arm, while spending approximately one hour less each day on the intervention arm. Hospital antimicrobial expenditures were $285,812 in the intervention arm and $370,006 in the control arm, for a savings of $84,194 (23%), or $37.64 per patient. No significant difference was observed in mortality (3.26% vs. 2.95%, p = 0.55) or length of hospitalization (3.84 vs. 3.99 days, p = 0.38). CONCLUSION: Use of the system facilitated the management of antimicrobial utilization by allowing the AMT to intervene on more patients receiving inadequate antimicrobial therapy and to achieve substantial time and cost savings for the hospital. This is the first study that demonstrates in a patient-randomized controlled trial that computerized clinical decision support systems can improve existing antimicrobial management programs.


Subject(s)
Anti-Infective Agents/therapeutic use , Decision Support Systems, Clinical , Drug Therapy, Computer-Assisted , Adult , Health Services Misuse , Humans , Reminder Systems
8.
J Antimicrob Chemother ; 58(1): 154-8, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16636084

ABSTRACT

OBJECTIVES: To evaluate the impact of the rapid differentiation of Staphylococcus aureus from coagulase-negative staphylococci (CoNS) in blood cultures using peptide nucleic acid fluorescence in situ hybridization (PNA FISH) on vancomycin usage, length of patient hospital stay and hospital costs. DESIGN: This was a retrospective, cost-effective analysis of PNA FISH in its initial 3 month implementation period in 2004 in a 650 bed academic medical centre. Blood cultures with Gram-positive cocci in clusters (GPCC) that were negative for S. aureus using the PNA FISH assay were compared with an untested control group in the same period that had similar illness severity and location. We evaluated the effectiveness of the early identification of CoNS by ruling out S. aureus in conjunction with an antimicrobial team (AMT) on antimicrobial therapy, patient length of stay and hospital costs. RESULTS: A total of 139 blood cultures positive with GPCC had PNA FISH results while 84 in the control group did not. Evaluable criteria were met in 53 patients in the PNA FISH group and 34 in the control group. When comparing the results obtained from using the PNA FISH assay with those for the control group, there was a significant reduction in median length of hospital stay from 6 to 4 days (P < 0.05, CI 0.95-1.87) and a trend towards less vancomycin usage with a decrease in associated hospital costs of approximately Dollars 4000 per patient. CONCLUSIONS: The PNA FISH assay is rapid, accurate and reliable and in association with an AMT could decrease hospital length of stay in patients with CoNS bacteraemia in non-intensive care unit settings and prevent excessive vancomycin usage.


Subject(s)
Bacteremia/microbiology , Staphylococcus/classification , Adult , Aged , Drug Utilization , Female , Hospitalization/economics , Humans , In Situ Hybridization , Length of Stay , Male , Middle Aged , Vancomycin/economics
SELECTION OF CITATIONS
SEARCH DETAIL